Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Linda Gardner

Mrs. Linda Gardner has over two decades of Interventional Radiology experience, prior to transitioning over to Nuclear Medicine in March of 2017. She is the Chief Nurse for the Peptide Receptor Radionuclide Therapy (PRRT) program, starting from the expanded access program (EAP) thru to the FDA approved commercial program. She has presented this program to a national, and international audience. Linda Gardner was the Chief Research Nurse for the Lu 177-PSMA-directed endo-radiotherapy of metastatic, castration-resistant prostate cancer clinical phase 2 trial at UCLA. UCLA has been one of the first institutions to administer Lu-177 PSMA-617 under the MAP (Managed access program) which is currently awaiting FDA approval. Linda Gardner is leading the ICPO Academy pillar for Nursing and Patients Relationships.